Loading...
Loading...
Aeterna Zentaris
AEZS today announced that the U.S. Food
and Drug Administration ("FDA") has accepted for filing the Company's
New Drug Application ("NDA") for its ghrelin agonist, macimorelin
acetate, in Adult Growth Hormone Deficiency ("AGHD"). The acceptance
for filing of the NDA indicates the FDA has determined that the
application is sufficiently complete to permit a substantive review.
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in